Follow The Filings

AUTL Autolus Therapeutics PLC

Health Care, filed as AUTOLUS THERAPEUTICS PLC (SPON ADS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $287K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.05%

Who owns AUTL

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.05% Hold 179,316 $287K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AUTL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AUTL insider trades
  • None no insider bought on the open market
  • $16K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Cintia Piccina U.S. CCO & Country Gen Manager
    Sale
    $16K 6,713 shares at $2.34 34% of stake
    Traded Sep 2 Filed Sep 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.05,7.01,9.01 Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01 Filing Doc
424B3 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — — $75.39M
Gross profit * — — -$20.98M
Gross margin * — — -27.8%
Net income -$208.38M -$220.66M -$287.53M
Net margin * — — -381.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $393.88M $660.93M $435.92M
Total non-current assets * $66.09M $121.8M $153.15M
Total assets $459.97M $782.72M $589.07M
Total current liabilities $39.64M $60.74M $73.44M
Total non-current liabilities * $153.41M $294.66M $337.5M
Total equity $266.92M $427.32M $178.13M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$145.59M -$206.27M -$283.57M
Cash from investing -$10.99M -$394.55M $158.46M
Cash from financing -$0.883M $589.55M -$4.34M
Net change in cash -$142.43M -$11.53M -$123.17M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.